Biotech Portfolio Rotation
Artia Global Partners Doubles Rapport Stake, Rotates Exposure Across Key Biotech Stocks
Key Points
In Rapport Therapeutics (RAPP), Artia Global Partners disclosed it owned 138,508 shares after buying an additional 73,900 shares, with the position valued at about $4.202 million and ranking as its 26th-largest holding.
Other investors also piled into Rapport: Russell Investments boosted its stake by 56.9% (to 2,282 shares), Mirae Asset Global Investments increased by 64.1% (to 2,316 shares), and Meeder Asset Management initiated a new position valued at roughly $37,000.
For Palvella Therapeutics (PVLA), Artia initiated/bought a new position of 59,200 shares worth about $6.196 million; the stock accounted for ~0.9% of Artia’s portfolio and was its 20th-largest position.
Palvella’s buying was broad: Summit Partners Public Asset Management increased its PVLA stake by 1,016.0% (to 389,420 shares), while State Street lifted its stake by 206.3% (to 420,462 shares) and Jennison Associates grew by 262.4% (to 387,483 shares).
For Alnylam Pharmaceuticals (ALNY), Artia cut its stake by selling 17,170 shares, leaving it with 17,400 shares (about 49.7% trimmed), according to the reported quarterly disclosure.
Artia Global Partners LP more than doubled its stake in Rapport Therapeutics during the fourth quarter, buying 73,900 additional shares to reach 138,508 total — a 114.4% increase valued at about $4.2 million, according to MarketBeat. The move was part of a broader biotech reshuffle that also saw Artia enter Palvella Therapeutics for the first time and slash its Alnylam Pharmaceuticals position nearly in half.
The disclosures, filed in February 2026 via Form 13F with the SEC, show Artia rotating out of a mature RNA-drug giant and into smaller, high-risk clinical-stage companies. Several other large funds made nearly identical moves at the same time, amplifying the market signal.
Rapport and Palvella Draw the Biggest New Money
Artia's Rapport stake — now its 26th-largest holding — drew company from several other funds. MarketBeat data shows Russell Investments grew its Rapport position by 56.9% to 2,282 shares, while Mirae Asset Global Investments added 64.1% to reach 2,316 shares. Meeder Asset Management opened a brand-new position worth roughly $37,000.
Palvella Therapeutics attracted even more aggressive buying. Artia initiated a new position of 59,200 shares worth $6.196 million — about 0.9% of its total portfolio. Summit Partners Public Asset Management went further, exploding its Palvella stake by 1,016% to 389,420 shares, according to SEC EDGAR filings. State Street added 206.3% to reach 420,462 shares, and Jennison Associates grew by 262.4% to 387,483 shares.
Alnylam Cut Nearly in Half as Artia Funds New Bets
To help pay for these new positions, Artia sold 17,170 shares of Alnylam Pharmaceuticals — cutting its stake by 49.7% and leaving just 17,400 shares. Alnylam is a large, established RNA-drug company with several products already on the market. Analysts at Bloomberg Tax describe this type of move as a classic "rebalancing" — funds shift money from proven companies into earlier-stage firms where the potential upside is much higher.
The logic is straightforward. Artia also lifted its NewAmsterdam Pharma position by 159%, adding it to the fund's top-30 holdings. Taken together, the Alnylam trim and the NewAmsterdam, Rapport, and Palvella additions paint a clear picture: Artia is trading safety for upside in neurology and rare-disease drugs.
EyePoint Gets a 22% Boost Amid Split Analyst Views
Artia also raised its Eyepoint Pharmaceuticals stake by 22.1%, bringing its total to 767,098 shares worth $14.02 million, according to Watchlist News. Vanguard and Federated Hermes made large increases in Eyepoint at the same time. The stock focuses on a long-acting eye implant called Duravyu, which is moving through late-stage clinical trials.
Analysts are split on the near-term outlook. Guggenheim raised its price target on Eyepoint with a "Buy" rating, citing strong underlying technology. But at least one other firm lowered its target while keeping an "Outperform" view, flagging what Defense World called "near-term clinical execution risks." That gap between bulls and cautious optimists reflects the broader uncertainty around Eyepoint's next data readout.
Crowded Trades Raise Concentration Risk Warning
The simultaneous rush into Palvella by Artia, State Street, Summit, and Jennison has raised flags among risk-focused analysts. When many large funds pile into a small-cap stock at once, it creates a "crowded trade." If a clinical trial fails, all those funds may try to sell at the same time — and there may not be enough buyers. This kind of exit rush has wiped out value in small biotech stocks before.
Rapport Therapeutics carries its own binary risk. The stock has a consensus "Moderate Buy" rating from ten research firms, with an average 12-month price target of $58.83, according to Ticker Report. Artia's $4.2 million position could grow sharply if the company's lead drug, RAP-219, hits its clinical marks — or fall hard if it doesn't. For now, the fund is betting on the upside.
Sentiment
Mostly PositivePublishers
10
Articles
6
Reach
16
